• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Upcoming Post-Conference Perspectives: ASH 2021

Video

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Related Videos
Peter Voorhees, MD, Atrium Health Levine Cancer Institute
Hearn Jay Cho, MD, PhD
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD
Kelley L. Julian, PharmD, BCOP
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD, Cancer Center Clínica Universidad de Navarra
Matias Sanchez, MD
Related Content
Multiple myeloma | Image Credit: © angellodeco-stock.adobe.com

BMI in CAR T: Overweight Status Predicts Worse MM Outcomes

November 29th 2025
Article

A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma (MM), highlighting the impact of overweight status on efficacy.

Read More

FDA approval | Image Credit: © muh-stock.adobe.com

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM

November 6th 2025
Article

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

Read More

Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP

Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP

October 31st 2025
Article

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring collaboration, patient-centered strategies, and AI.

Read More

Multiple myeloma | Image Credit: © Dzmitry-stock.adobe.com

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

October 22nd 2025
Article

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

Read More

Teclistamab | Image Credit: © luchschenF-stock.adobe.com

Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting

September 24th 2025
Article

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

Read More

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com

Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025
Article

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.